TI
CYTK icon

Trexquant Investment’s Cytokinetics CYTK Stock Holding History

Trexquant Investment’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.81M Buy
115,134
+66,944
+139% +$4.81M 0.06% 437
2026
Q1 		$3.18M Buy
+48,190
New +$3.06M 0.02% 830
2025
Q3 		– Sell
-10,894
Closed -$360K – 1657
2025
Q2 		$360K Buy
+10,894
New +$379K ﹤0.01% 1344
2024
Q3 		– Sell
-28,508
Closed -$1.54M – 1584
2024
Q2 		$1.54M Sell
28,508
-77,631
-73% -$4.69M 0.02% 840
2024
Q1 		$7.44M Sell
106,139
-3,671
-3% -$284K 0.15% 194
2023
Q4 		$9.17M Buy
109,810
+88,342
+412% +$3.2M 0.21% 114
2023
Q3 		$632K Buy
+21,468
New +$715K 0.02% 922
2021
Q3 		– Sell
-19,266
Closed -$381K – 1207
2021
Q2 		$381K Buy
+19,266
New +$452K 0.03% 608
2020
Q4 		– Sell
-31,092
Closed -$673K – 1101
2020
Q3 		$673K Sell
31,092
-10,781
-26% -$252K 0.04% 557
2020
Q2 		$987K Sell
41,873
-24,252
-37% -$455K 0.07% 404
2020
Q1 		$780K Buy
66,125
+35,493
+116% +$453K 0.06% 494
2019
Q4 		$325K Buy
+30,632
New +$315K 0.02% 712
2019
Q1 		– Sell
-44,016
Closed -$278K – 1047
2018
Q4 		$278K Buy
+44,016
New +$323K 0.02% 812
2018
Q1 		– Sell
-14,470
Closed -$118K – 1129
2017
Q4 		$118K Buy
14,470
+3,914
+37% +$44.4K 0.01% 998
2017
Q3 		$153K Sell
10,556
-4,375
-29% -$59.8K 0.04% 685
2017
Q2 		$181K Sell
14,931
-47,450
-76% -$659K 0.05% 686
2017
Q1 		$802K Buy
+62,381
New +$729K 0.1% 347
2016
Q2 		– Sell
-112,403
Closed -$792K – 914
2016
Q1 		$792K Buy
+112,403
New +$821K 0.09% 374
2015
Q3 		– Sell
-56,300
Closed -$378K – 1073
2015
Q2 		$378K Buy
+56,300
New +$369K 0.04% 736

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trexquant Investment's CYTK Position: Q2 2026 in Review

Trexquant Investment increased its Cytokinetics (CYTK) stake by 139% in Q2 2026, buying an estimated $4.81M and bringing the position to 115,134 shares worth $9.81M. The position accounts for 0.06% of the portfolio, ranked #437.

Trexquant Investment first reported a position in CYTK in Q2 2015 and has held it in 19 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Trexquant Investment held 115,134 shares of Cytokinetics worth $9.81M as of Q2 2026.
  • Trexquant Investment bought 66,944 Cytokinetics shares in Q2 2026, an estimated $4.81M.
  • Cytokinetics made up 0.06% of Trexquant Investment's portfolio in Q2 2026, its #437 holding.
  • Trexquant Investment first reported a position in Cytokinetics in Q2 2015 and has held it in 19 quarters since.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.